Related Experiment Video
Updated: May 28, 2026

Optimizing Tubulin Yield from Porcine Brain Tissue
Published on: October 11, 2024
[Antitubulin agents]
1Hospices civils de Lyon, université Lyon-I, centre de recherche en cancérologie de Lyon, France. charles.dumontet@chu-lyon.fr
Abstract:
Microtubules are dynamic filamentous cytoskeletal proteins that are an important therapeutic target in patients with tumors. Microtubule binding agents have been part of the pharmacopoeia of cancer for decades, and until the advent of targeted therapy microtubules represented the only alternative to DNA as a therapeutic target in cancer. There are currently a variety of available vinca alkaloids and taxanes and other agents, such as ixabepilone and eribulin, have also been approved. Maytansinoids have been used for the production of immunoconjugates, monoclonal antibodies covalently bound to antimitotic molecules. The screening of a variety of botanical species and marine organisms continues to yield promising new antitubulin agents with novel properties. Enhanced tumor specificity, reduced neurotoxicity, and insensitivity to chemoresistance mechanisms are the three main objectives in the current search for novel microtubule binding agents.
Insights
Microtubule binding agents are crucial cancer therapies. Current research focuses on developing novel agents with improved tumor specificity and reduced toxicity for better cancer treatment outcomes.
Area of Science:
- Oncology
- Cell Biology
- Pharmacology
Background:
- Microtubules are essential cytoskeletal components and validated targets for cancer chemotherapy.
- Microtubule-targeting agents, including vinca alkaloids and taxanes, have been mainstays in cancer treatment for decades.
- Novel agents like ixabepilone and eribulin, alongside maytansinoid-based immunoconjugates, expand therapeutic options.
Purpose of the Study:
- To review the current landscape of microtubule binding agents in cancer therapy.
- To highlight ongoing research efforts in discovering novel antitubulin compounds.
- To identify key objectives for future drug development in this area.
Main Methods:
- Review of existing literature on microtubule binding agents.
- Analysis of approved drugs and ongoing clinical investigations.
- Exploration of screening programs for new botanical and marine-derived agents.
Main Results:
- A diverse range of microtubule binding agents are approved and in development.
- Maytansinoids are utilized in antibody-drug conjugates for targeted delivery.
- Screening of natural sources continues to identify promising new antitubulin compounds.
Conclusions:
- Novel microtubule binding agents are actively being sought to overcome limitations of current therapies.
- Key goals include enhancing tumor specificity and reducing neurotoxicity.
- Developing agents insensitive to chemoresistance mechanisms is a critical objective for improved cancer treatment.
More Related Videos
Related Concept Videos
Drugs that Stabilize Microtubules
Anthelminthic Agents
Drugs that Destabilize Microtubules
Destabilization of Microtubules
Microtubules
Microtubules
Microtubules have two structurally similar globular protein subunits: α and β tubulins. In the cytosol, the α and β tubulins form a heterodimer. These αβ-heterodimers...

